News for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ...

SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. , a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. , yesterday entered into a license agreement... | March 28, 2023

CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that it has closed a…